Inactive Instrument

Amarin Corporation plc (ADR) Stock Xetra

Equities

EH3A

US0231112063

Biotechnology & Medical Research

End-of-day quote Xetra
- EUR - Intraday chart for Amarin Corporation plc (ADR)

Financials

Sales 2024 * 202M 189M 276M Sales 2025 * 215M 201M 294M Capitalization 292M 273M 400M
Net income 2024 * -70M -65.33M -95.75M Net income 2025 * -64M -59.73M -87.54M EV / Sales 2024 * 1.23 x
Net cash position 2024 * 43.92M 40.99M 60.07M Net cash position 2025 * 159M 148M 217M EV / Sales 2025 * 0.62 x
P/E ratio 2024 *
-4.03 x
P/E ratio 2025 *
-4.28 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 90.48%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Amarin Corporation plc (ADR)

Managers TitleAgeSince
Chief Executive Officer 61 12-10-31
Director of Finance/CFO 52 22-06-19
Compliance Officer 55 11-14
Members of the board TitleAgeSince
Director/Board Member 45 23-02-27
Chairman 49 23-02-27
Director/Board Member 66 23-02-27
More insiders
Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.
More about the company